Tbio ATF2 Cyclic AMP-dependent transcription factor ATF-2

Protein Summary

Description

Transcriptional activator which regulates the transcription of various genes, including those involved in anti-apoptosis, cell growth, and DNA damage response. Dependent on its binding partner, binds to CRE (cAMP response element) consensus sequences (5'-TGACGTCA-3') or to AP-1 (activator protein 1) consensus sequences (5'-TGACTCA-3'). In the nucleus, contributes to global transcription and the DNA damage response, in addition to specific transcriptional activities that are related to cell development, proliferation and death. In the cytoplasm, interacts with and perturbs HK1- and VDAC1-containing complexes at the mitochondrial outer membrane, thereby impairing mitochondrial membrane potential, inducing mitochondrial leakage and promoting cell death. The phosphorylated form (mediated by ATM) plays a role in the DNA damage response and is involved in the ionizing radiation (IR)-induced S phase checkpoint control and in the recruitment of the MRN complex into the IR-induced foci (IRIF). Exhibits histone acetyltransferase (HAT) activity which specifically acetylates histones H2B and H4 in vitro. In concert with CUL3 and RBX1, promotes the degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM. Can elicit oncogenic or tumor suppressor activities depending on the tissue or cell type. This gene encodes a transcription factor that is a member of the leucine zipper family of DNA binding proteins. The encoded protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions This protein binds to the cAMP-responsive element (CRE), an octameric palindrome. It forms a homodimer or a heterodimer with c-Jun and stimulates CRE-dependent transcription. This protein is also a histone acetyltransferase (HAT) that specifically acetylates histones H2B and H4 in vitro; thus it may represent a class of sequence-specific factors that activate transcription by direct effects on chromatin components. The encoded protein may also be involved in cell's DNA damage response independent of its role in transcriptional regulation. Several alternatively spliced transcript variants have been found for this gene [provided by RefSeq, Jan 2014]

Uniprot Accession IDs

• P15336
• A1L3Z2
• A4D7U4
• A4D7U5
• A4D7V1
• D3DPE9
• G8JLM5
• Q13000
• Q3B7B7
• Q4ZFU9
• Q53RY2
• Q8TAR1
• Q96JT8
• cAMP-dependent transcription factor ATF-2

Gene Name

• ATF2

Ensembl ID

• ENST00000264110
• ENSP00000264110
• ENSG00000115966
• ENST00000345739
• ENSP00000340576
• ENST00000392544
• ENSP00000376327
• ENST00000409499
• ENSP00000386282
• ENST00000409635
• ENSP00000387093
• ENST00000409833
• ENSP00000386526
• ENST00000426833
• ENSP00000407911

Symbol

• CREB2
• CREBP1
• HB16
• CREB2
• TREB7
• CREB-2
• CRE-BP1

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
hub protein	1
kinase	1
molecular function	1
co-expressed gene	0.99
biological process	0.98

Protein Classes

PANTHER Classes

Protein / ... / Basic Leucine Zipper Transcription Factor / Cyclic Amp-dependent Transcription Factor Atf-2

DTO Classes

Protein / Transcription Factor / Basic Leucine Zipper Transcription Factor / Cyclic Amp-dependent Transcription Factor Atf-2

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 249.72   (req: < 5)

Gene RIFs: 136   (req: <= 3)

Antibodies: 2316   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 249.72   (req: >= 5)

Gene RIFs: 136   (req: > 3)

Antibodies: 2316   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 38

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0